| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-N-amido-PEG4-acid does not have a biological target; it is a chemical linker for bioconjugation. The Fmoc group can be deprotected under basic conditions to obtain a free amine. The terminal carboxylic acid enables coupling to amine-containing molecules. The PEG4 spacer improves solubility, reduces aggregation, and enhances the pharmacokinetic properties of conjugated molecules.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC. Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC targets and selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system.
In vitro activity is not applicable as this is a chemical linker. It is used in the synthesis of antibody-drug conjugates (ADCs) and PROTACs. Its utility lies in its chemical reactivity and the properties it imparts to conjugated molecules, including enhanced aqueous solubility and reduced aggregation in peptides or bioconjugates. |
| ln Vivo |
In vivo activity is not applicable as this is a chemical linker used for in vitro synthesis. It is not a therapeutic agent. Its applications are in the chemical synthesis of bioconjugates for drug delivery and targeted therapy. The properties of the PEG4 spacer influence the pharmacokinetics of the final conjugate.
|
| Enzyme Assay |
For non-cellular assays, Fmoc-N-amido-PEG4-acid is used in chemical conjugation reactions. The carboxylic acid group is activated with coupling reagents to form amide bonds with amines. The Fmoc group is removed with piperidine for subsequent reactions. Reaction progress is monitored by analytical techniques. The compound serves as a building block for more complex molecules.
|
| Cell Assay |
In vitro cellular assays are not applicable as this compound is a chemical linker. It may be used to synthesize conjugates that are later tested in cellular assays, but the linker itself does not have direct cellular activity. Its PEG4 spacer contributes to the solubility and biocompatibility of the final conjugate.
|
| Animal Protocol |
In vivo animal experiments are not applicable as this compound is a chemical linker. It is used in the synthesis of conjugates that may be tested in animal models. The PEG4 spacer influences the pharmacokinetic properties of the final conjugate, including circulation half-life, immunogenicity, and biodistribution.
|
| ADME/Pharmacokinetics |
Fmoc-N-amido-PEG4-acid has a molecular weight of 487.6 and a molecular formula of C₂₆H₃₃NO₈. Purity is ≥98%. The compound is typically stored at -20°C. It is soluble in organic solvents such as DMSO and DMF. The PEG4 spacer provides good hydrophilicity and flexibility to conjugated molecules.
|
| Toxicity/Toxicokinetics |
Fmoc-N-amido-PEG4-acid is a chemical reagent and is not intended for therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. It may cause skin irritation (H315), serious eye irritation (H319), respiratory irritation (H335), and is harmful if swallowed, in contact with skin, or if inhaled (H302+H312+H332).
|
| References | |
| Additional Infomation |
Fmoc-N-amido-PEG4-acid is a PEG linker used in ADC development and PROTAC synthesis. The Fmoc group provides orthogonal protection for the amine, enabling selective deprotection under mild conditions for precise stepwise synthesis. The PEG4 spacer enhances solubility and reduces aggregation in peptides or bioconjugates. The compound is available from various commercial suppliers.
|
| Molecular Formula |
C26H33NO8
|
|---|---|
| Molecular Weight |
487.5421
|
| Exact Mass |
487.221
|
| CAS # |
557756-85-1
|
| PubChem CID |
2756186
|
| Appearance |
Colorless to light yellow viscous liquid
|
| Density |
1.219
|
| LogP |
3.457
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
35
|
| Complexity |
596
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(N([H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])C(=O)O[H])=O)C([H])([H])C1([H])C2=C([H])C([H])=C([H])C([H])=C2C2=C([H])C([H])=C([H])C([H])=C12
|
| InChi Key |
NUHRPLKTAAVHCZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H33NO8/c28-25(29)9-11-31-13-15-33-17-18-34-16-14-32-12-10-27-26(30)35-19-24-22-7-3-1-5-20(22)21-6-2-4-8-23(21)24/h1-8,24H,9-19H2,(H,27,30)(H,28,29)
|
| Chemical Name |
3-[2-[2-[2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~205.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.13 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.13 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0511 mL | 10.2556 mL | 20.5111 mL | |
| 5 mM | 0.4102 mL | 2.0511 mL | 4.1022 mL | |
| 10 mM | 0.2051 mL | 1.0256 mL | 2.0511 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
